<DOC>
	<DOCNO>NCT01745783</DOCNO>
	<brief_summary>This phase I / II evaluation safety feasibility intravenous infusion mesenchymal cell autologous bone marrow patient Multiple Sclerosis . Intravenous administration autologous mesenchymal cell bone marrow feasible safe effective treating patient suffer multiple sclerosis .</brief_summary>
	<brief_title>Mesenchymal Cells From Autologous Bone Marrow , Administered Intravenously Patients Diagnosed With Multiple Sclerosis</brief_title>
	<detailed_description>The study population consist total 30 patient diagnosed multiple sclerosis , meet inclusion criterion none exclusion set express agreement participate study signing informed consent whose result clinically evaluable . Selected patient consent enrol trial randomize one follow group : - Group 1 receive single intravenous administration cellular product Day 0 placebo infusion day + 180 . - Group 2 receive placebo infusion day 0 single cell product administration day +180 . Randomization 1:1 , 15 patient receive cellular product Day 0 ( Group 1 ) 15 patient day +180 ( group 2 ) , always maintain time double-blind status test ( patient researcher ) . The bone marrow extract patient immediately inclusion study , local anesthesia sedation . For patient group 1 autologous mesenchymal cell obtain bone marrow infuse immediately time necessary production . For patient group 2 , bone marrow cell freeze later procedure mesenchymal cell infusion six month . Patients evaluate clinical , radiological , electrophysiological well detailed section 8 corresponding Development Test Evaluation Response . It estimate inclusion period approximately 12-18 month , patient track another twelve month . Therefore total duration study 24 30 month inclusion first patient completion follow-up period last patient include . Study objective : - Main objective : 1 . To evaluate safety intravenous infusion autologous bone marrow mesenchymal cell multiple sclerosis patient diagnose evaluate complication adverse effect therapy study procedure . 2 . Assessing difference number lesion magnetic resonance image gadolinium , group undergo treatment week 4 , 12 24 . - Secondary objective : 1 . To evaluate feasibility efficacy indication treatment analysis comparative result exploratory clinical variable patient baseline ( pretreatment ) 6 12 month follow-up . 2 . Compare result safety , feasibility efficacy administration initial cell therapy treatment ( day 0 ) delay ( day +180 ) . 3 . Evaluating immunomodulatory effect treatment quantify cell subset cytokine , functional analysis immune response . Cerebrospinal fluid metabolomic profile gene expression cell present blood cerebrospinal fluid , aim identify new biomarkers diagnosis interest , prognosis monitoring , potential therapeutic target derive . 4 . Providing result study propose International Mesenchymal Stem Cell Transplant Study Group whose directive perform test .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>1 . Patients diagnose MS inflammatory form : 1 . Course outbreak ( relapse remit ) , respond least one year treatment one approve therapy ( beta interferon , glatiramer acetate , natalizumab , mitoxantrone , fingolimod ) , confirm one follow criterion : ( ii ) At least one clinically document outbreak past 12 month . ( iii ) At least two clinically document outbreak last 24 month ( iv ) At least one lesion gadolinium MRI perform last 12 month . b . Secondary progressive form respond least one year treatment one approve therapy ( interferon beta , glatiramer acetate , natalizumab , mitoxantrone , fingolimod ) . That meet follow criterion : ( ) Increase 1 point baseline EDSS score less equal 5.0 , 0.5 point increase baseline score great equal 5.5 , last 12 month . ( ii ) least one clinically document outbreak least one lesion gadolinium MRI within last 12 month . c . Primary progressive form meet follow three criterion : ( ) Increase 1 point baseline EDSS score less equal 5.0 , 0.5 point increase baseline score great equal 5.5 , last 12 month . ( ii ) At least 1 lesion gadolinium MRI within last 12 month . ( iii ) oligoclonal band cerebrospinal fluid ( CSF ) . 2 . Normal laboratory parameter , define : Leukocytes ≥ 3000 Neutrophils ≥ 1500 Platelets ≥ 100,000 Aspartate aminotransferase ( AST ) / Alanine aminotransferase ( ALT ) ≤ 2.5 standard range institution Creatinine ≤ 2.5 mg / dl 3 . Patients sex age 18 50 . 4 . Disease duration ≥ 2 year ≤ 10 year . 5 . EDSS ( Expanded Disability Status Scale ) 3.0 6.5 point . 6 . Patients give informed consent participation clinical trial consent . 7 . Women childbearing potential must negative result pregnancy test time inclusion study agree use medically approve method contraception study 1 . Any active chronic infection , include Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) HIV . 2 . Immunosuppressive therapy 3 month prior randomization ( include natalizumab fingolimod ) . 3 . Treatment interferon beta glatiramer acetate 30 day prior randomization . 4 . Corticosteroid therapy 30 day prior randomization . 5 . Time since last exceed 60 day prior randomization outbreak . 6 . History malignancy ( basal cell carcinoma skin carcinoma situ exclude remission year ) . 7 . Life expectancy severely limit co morbidity . 8 . Previous history myelodysplasia hematological disease , clinically relevant change currently leukocyte count . 9 . Pregnancy / risk pregnancy ( include refusal use contraception ) 10 . Renal failure ( eGFR &lt; 60 mL/min/1.37m2 ) 11 . Inability undergo MRI scan 12 . Inability give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>